Company news
Aroa Biosurgery Ltd news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
US CMS Confirms Symphony Outpatient Reimbursement Rate
November 8, 2026
Aroa Biosurgery H1 FY27 Results & Investor Event
November 3, 2026
AROA Appoints Mark Dunwoodie as CFO
November 2, 2026
Change in substantial shareholding for ARX
October 18, 2026
Molnlycke to Co-promote Endoform In the US
October 15, 2026
Notification of cessation of securities - ARX
October 12, 2026
Investor Presentation - Symphony RCT
October 11, 2026
Invite to Investor Webinar on Symphony RCT
October 6, 2026
Investor Presentation - MASTRR Interim Analysis
October 6, 2026
Change in substantial holding
October 6, 2026
Symphony™ Randomized Controlled Trial Demonstrates Significantly Improved Healing of Diabetic Foot Ulcers
October 5, 2026
Symphony Significantly Improves DFU Healing
October 4, 2026
Invite to Investor Webinar on MASTRR Interim Analysis
September 28, 2026
Peer-reviewed 411-patient study reports low infection rates with Myriad™ in complex soft tissue reconstruction
September 6, 2026
Myriad MASTRR Study Reports Low Infection Rates
September 3, 2026
Change of Director's Interest Notice - BW
August 27, 2026
Notification regarding unquoted securities - ARX
August 27, 2026
Final Director's Interest Notice - JD
August 20, 2026
Results of Annual General Meeting
August 19, 2026
CEO Presentation - AGM
August 18, 2026
Chairman's Address - AGM
August 18, 2026
Notification of cessation of securities - ARX
August 11, 2026
Notification regarding unquoted securities - ARX
August 11, 2026
Change in substantial shareholding for ARX
August 6, 2026
Notification regarding unquoted securities - ARX
July 27, 2026
Commercial Leadership Appointments
July 27, 2026
FY26 Full Year Results Presentation
May 25, 2026
FY26 Appendix 4E and Full Year Results
May 25, 2026
ARX FY26 Preliminary Results
April 29, 2026
Symphony Randomised Control Trial Complete
March 29, 2026
AROA Business Update Presentation
February 2, 2026
AROA Business Update
February 2, 2026
Study demonstrates effectiveness and economic value of Myriad™ in trauma and acute care surgery.
January 20, 2026
Aroa Biosurgery H1 FY26 Results
November 24, 2025
Appendix 4D and Half Year Report
November 24, 2025
September 2025 Quarterly Report and Appendix 4C
October 15, 2025
First clinical evidence published on AROA's ENIVO™ system for surgical dead space management.
August 26, 2025
June 2025 Quarterly Report and Appendix 4C
July 28, 2025
FY25 Full Year Results Presentation
May 28, 2025
FY25 Appendix 4E and Full Year Results
May 28, 2025
AROA hits evidence milestone with real-world study validating the efficacy of Endoform in treating challenging venous leg ulcers.
May 1, 2025
March 2025 Quarterly Report and Appendix 4C
April 28, 2025
December 2024 Quarterly Report and Appendix 4C
January 28, 2025
Aroa Half Year Results Presentation
November 25, 2024
Aroa Biosurgery Half Yearly Results H1 FY25
November 25, 2024
September 2024 Quarterly Report and Appendix 4C
October 21, 2024
June 2024 Quarterly Report and Appendix 4C
July 23, 2024
FY24 Full Year Results Presentation
May 20, 2024
FY24 Appendix 4E and Full Year Results
May 20, 2024
March 2024 Quarterly Report and Appendix 4C
April 29, 2024
Decks
The 5 newest of 39 decks. Every deck is listed under its year.
- Investor Presentation (October 2026)
Investor deck · 26 slides · Oct 12, 2026
- Technical Presentation (October 2026)
Technical · 23 slides · Oct 7, 2026
- Shareholder Meeting (August 2026)
Shareholder meeting · 11 slides · Aug 19, 2026
- FY2026 Earnings Presentation
Earnings · 31 slides · May 26, 2026
- FY2026 Earnings Presentation
Earnings · 30 slides · May 26, 2026